Zacks Investment Research on MSN17d
United Therapeutics Stock Down Despite Q4 Earnings & Sales BeatUnited Therapeutics’ UTHR fourth-quarter 2024 earnings of $6.19 per share beat the Zacks Consensus Estimate of $6.10. Earnings rose 42% year over year on the back of higher product sales. See the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback